Riskpilot← Back to searchSign inGet full accessFisher Scientific Oy
OYActiveY-tunnus 2281126-9Ratastie 2Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20093 employeeswww.fishersci.fi
Revenue 2024
EUR 12,1M
+9% vs 2023
EBITDA margin
3.4%
+9% vs 2023
Equity ratio
31.8%
Financial strength
Net profit 2024
EUR 450K
+24% vs 2023
| Revenue | EUR 12,1M | +9% |
| EBITDA | EUR 410K | +9% |
| Net profit | EUR 450K | +24% |
| Total assets | EUR 6,3M | +23% |
| Equity | EUR 2M | +29% |
| Employees | 3 | — |
Legal name
Fisher Scientific Oy
Y-tunnus number
2281126-9
Legal form
Osakeyhtiö
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
13. elokuuta 2009
Share capital
EUR 1 502 500
Employees
3 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen jäsen, toimitusjohtaja ja toimitusjohtajan sijainen kukin yksin
Company purpose
Yhtiön toimialana on laboratorio- ja sairaalatarvikkeiden, analyyttisten mittalaitteiden, reagenssien ja diagnostisten valmisteiden, lääketieteellisten ja teknisten laitteiden, instrumenttien ja niihin liittyvien kulutustavaroiden tuonti ja vienti, tukku- ja vähittäiskauppa sekä alan koulutus ja konsultointi. Yhtiö voi omistaa ja hallita kiinteistöjä, arvopapereita, osakkeita ja osuuksia.
Address
Ratastie 2
Phone
+35809802766
Website
www.fishersci.fi
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 8 542 | 9 496 | 10 726 | 11 112 | 12 090 |
| Staff expenses | −219 | −272 | −272 | −291 | −0 |
| EBITDA | 58 | 347 | 510 | 377 | 410 |
| Depreciation & amort. | — | — | — | −0 | −0 |
| EBIT | 58 | 347 | 510 | 377 | 410 |
| Net financials | −11 | −28 | −27 | −15 | 39 |
| Profit before tax | 48 | 320 | 482 | 362 | 450 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | 48 | 320 | 482 | 362 | 450 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 953 | 2 129 | 3 210 | 5 138 | 6 321 |
| Equity | 398 | 718 | 1 200 | 1 563 | 2 012 |
| Long-term debt | 17 | 11 | 11 | 0 | 99 |
| Short-term debt | 1 538 | 1 400 | 1 999 | 0 | 4 210 |
| Total debt | 1 555 | 1 411 | 2 010 | 0 | 4 309 |
EBITDA margin
3.4%
This company
15.8%
Market median
-78% vs market
20202024
Equity ratio
31.8%
This company
38.2%
Market median
+17% vs market
20202024
Return on equity
22.3%
This company
18.4%
Market median
+21% vs market
20202024
Net profit margin
3.7%
This company
8.1%
Market median
-54% vs market
20202024
Asset turnover
1.91×
This company
1.12×
Market median
+71% vs market
20202024
Debt / equity
2.14×
This company
0.62×
Market median
-245% vs market
20202024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JM Confidential Clerk | Confidential Clerk | 2025 |
| Former (3) | ||
MB Confidential Clerk | Confidential Clerk | 2016 – 2019 |
| Audit | 2016 – 2023 | |
EU Confidential Clerk | Confidential Clerk | 2019 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Chairperson | 2017 | |
| Board of Directors | 2025 | |
| Board of Directors | 2022 | |
| Board of Directors | 2020 | |
| Former (5) | ||
| Board of Directors | 2020 – 2022 | |
| Board of Directors | 2017 – 2020 | |
| Board of Directors | 2024 – 2025 | |
| Board of Directors | 2017 – 2024 | |
| Board of Directors | 2017 – 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Fisher Scientific Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jani Markus Holopainen | Confidential Clerk | 0 companies |
| Mikael Bill Ivar Östman | Confidential Clerk | 0 companies |
| Christian Savtschenko-Alexandroff | Audit | 0 companies |
| Eeva-Reetta Uitti | Confidential Clerk | 0 companies |
| Lynn Gray | Board of Directors | 0 companies |
| Linda Carina Carlsson | Board of Directors | 0 companies |
| Carolin Sonja Freidel | Board of Directors | 0 companies |
| Petrus Thomas Adrianus van der Zande | Chairperson | 0 companies |
| Arabella Lucy Mary von Habsburg Lothringen | Board of Directors | 0 companies |
| Thomas Arthur Nicholson | Board of Directors | 0 companies |
| Monica Del Carmen Manotas Urueta | Board of Directors | 0 companies |
| Sara Maria Carrella | Board of Directors | 0 companies |
| Richard Lawrence Spoor | Board of Directors | 0 companies |